本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Sol-Gel Technologies

65.00
-0.2700-0.41%
盤後65.000.00000.00%16:10 EST
成交量:1.67萬
成交額:108.02萬
市值:1.81億
市盈率:-20.15
高:65.50
開:64.80
低:63.57
收:65.27
52周最高:75.00
52周最低:4.02
股本:278.58萬
流通股本:68.93萬
量比:0.64
換手率:2.42%
股息:- -
股息率:- -
每股收益(TTM):-3.2257
每股收益(LYR):-3.7979
淨資產收益率:-29.59%
總資產收益率:-16.48%
市淨率:6.96
市盈率(LYR):-17.11

資料載入中...

公司資料

公司名字:
Sol-Gel Technologies
交易所:
NASDAQ
成立時間:
1997
員工人數:
34
公司地址:
7 Golda Meir Street,Weizmann Science Park,Ness Ziona,Israel
郵編:
7403650
傳真:
- -
簡介:
Sol-gel Technologies Ltd.1997年10月28日根據以色列國法律註冊成立。該公司是一家創新型皮膚病學公司,擁有兩項NDA批準的成功記錄,以及正在為孤兒適應症開發的先進候選產品管道。Sol-Gel成功研發開創性外用藥物Twyneo和Epsolay,分別獲批用於紅斑痤瘡和炎症性病變的治療。

董事

名稱
職位
Alon Seri Levy
Chief Executive Officer and Director
Moshe Arkin
Chairman of the Board
Jerrold S. Gattegno
External Director
Ran Gottfried
External Director
Hani Lerman
Director
Itai Arkin
Director
Jonathan B. Siegel
Director
Shmuel Ben Zvi
Director
Yaffa Krindel Sieradzki
Director

股東

名稱
職位
Alon Seri Levy
Chief Executive Officer and Director
Gilad Mamlok
Chief Financial Officer
Dov Zamir
Vice President Special Projects
Itzik Yosef
Vice President Operations
John Vieira
U.S. Head of Commercialization
Karine Neimann
Vice President Projects and Planning, Chief Chemist
Nissim Bilman
Vice President Quality
Ofer Toledano
Vice President Research and Development
Ofra Levy Hacham
Vice President Clinical and Regulatory Affairs